Immunity for Health

IfH Symposium: Innovations in Antibody-Based Biologics

11 Jun 2026 | Landmark Building, UZ Brussels, Belgium

ABSCINT

Biotech / Medtech / Start-up

Liège, Belgium
10 profile visits

About

ABSCINT is a Belgian biotechnology spin-off (founded in 2020) headquartered in Liège, specialising in cutting-edge molecular imaging diagnostics.

Core Technology & Mission

The company develops in vivo PET (Positron Emission Tomography) tracers using radio‑labeled single‑domain antibodies (sdAbs).

These sdAb tracers enable:

  • Highly specific, rapid whole‑body imaging of molecular targets (e.g., HER2)

  • Fast results—full-body scans within 60–90 minutes post-injection

  • Minimal radiation dose and no need for patient hospitalization due to quick tracer clearance .

Their stated mission is to transform HER2‑related cancer care by accelerating the diagnostic journey and enabling personalized treatment decisions

HEALTH SECTOR

Human health

CLINICAL DEVELOPMENT AND TRIALS

Clinical trials

THERAPEUTIC AREAS

Oncology

RESEARCH AND DEVELOPMENT

Diagnostics

Representatives

CEO

ABSCINT